Health Catalyst, Inc. (NASDAQ:HCAT) Short Interest Down 9.5% in July

Health Catalyst, Inc. (NASDAQ:HCAT) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,200,000 shares, a decline of 9.5% from the July 15th total of 2,430,000 shares. Based on an average trading volume of 571,300 shares, the short-interest ratio is presently 3.9 days.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on HCAT. Evercore ISI dropped their target price on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research note on Friday, August 9th. Piper Sandler dropped their price target on Health Catalyst from $15.00 to $14.00 and set an “overweight” rating on the stock in a report on Thursday, June 6th. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 price objective on shares of Health Catalyst in a research note on Tuesday, May 21st. Finally, Wells Fargo & Company lowered their target price on Health Catalyst from $14.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, May 10th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Insider Activity at Health Catalyst

In other news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $6.19, for a total transaction of $32,243.71. Following the transaction, the chief operating officer now owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 13,035 shares of company stock worth $81,396 in the last quarter. Company insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of large investors have recently made changes to their positions in HCAT. Nisa Investment Advisors LLC grew its holdings in shares of Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after acquiring an additional 5,232 shares during the period. Quarry LP raised its holdings in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares in the last quarter. Perfromance Wealth Partners LLC purchased a new position in Health Catalyst during the second quarter valued at $64,000. Mackenzie Financial Corp bought a new stake in shares of Health Catalyst during the 2nd quarter valued at $70,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Health Catalyst in the 4th quarter worth about $108,000. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Price Performance

NASDAQ HCAT traded down $0.01 during trading on Friday, hitting $6.76. 556,798 shares of the company’s stock traded hands, compared to its average volume of 598,123. The stock has a fifty day moving average of $6.62 and a two-hundred day moving average of $7.19. Health Catalyst has a 12-month low of $5.42 and a 12-month high of $12.45. The firm has a market cap of $398.78 million, a P/E ratio of -3.65 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The firm had revenue of $75.90 million for the quarter, compared to analysts’ expectations of $74.96 million. Health Catalyst had a negative net margin of 35.56% and a negative return on equity of 11.86%. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.21) earnings per share. As a group, analysts expect that Health Catalyst will post -0.4 earnings per share for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.